RxDoctor Payments Data

Richard Bang, MD

Family Medicine · Laredo, TXNPI 1467442848

Payments from drug & device makers

$2,292in general payments, 2019–2025

Across 97 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$486
  • Lilly USA, LLC$314
  • AstraZeneca$275
  • Johnson & Johnson$256
  • AbbVie$192
  • Biohaven Pharmaceuticals, Inc.$185
  • plus $585 from 17 others

What the payments were for

  • Food & beverage$2,292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,292 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$32,166
Medicare patients
86
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$121,065
RybelsusSemaglutide36$53,391
MounjaroTirzepatide29$38,883
JardianceEmpagliflozin32$38,387
FarxigaDapagliflozin Propanediol35$37,741
JanuviaSitagliptin Phosphate26$29,966
TrulicityDulaglutide21$29,829
Lisdexamfetamine Dimesylate12$1,800
Metoprolol Succinate71$1,373
Omeprazole74$1,293
Levothyroxine Sodium98$1,117
Testosterone Cypionate23$1,054
Pioglitazone Hcl105$1,027
ValacyclovirValacyclovir Hcl16$903
Hydroxyzine Hcl24$837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$486$174,456143 claims
Lilly USA, LLCMounjaro, Trulicity$314$68,71250 claims
Boehringer IngelheimJardiance$51$38,38732 claims
AstraZenecaFarxiga$275$37,74135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →